

PharmaEssentia*(FDA, Approval)*

FDA approves PharmaEssentia's BESREMi to treat adults with Essential Thrombocythemia, regardless of genotype or disease status

Ionis*(FDA, Approval)*

Ionis' ZANVASTRO gets FDA approval to treat Alexander disease in pediatric and adults patients

AstraZeneca*(FDA, Approval)*

FDA provides approval to AstraZeneca's ETCAMAH, in combination with CDK 4/6 inhibitor, to treat adults with HR-positive, HER2- negative, locally advanced or metastatic breast cancer

AstraZeneca*(EU, Approval)*

AstraZeneca's ENHERTU, in combination with pertuzumab, gets EU approval to treat adults with unresectable or metastatic HER2-positive breast cancer



► Shionogi*(TGA, Approval)*

Shionogi receives marketing authorization from TGA for cefiderocol to treat carbapenem-resistant Gram-negative bacterial infections

► Biogen*(NMPA, Approval)*

NMPA approves Biogen's LEQEMBI SC-AI formulation as an initiation treatment for MCI due to AD or for mild AD dementia

► Samsung Bioepis*(PMDA, Approval)*

PMDA of Japan grants marketing approval to Samsung Bioepis' biosimilar, NIPRO IV infusion 130mg, indicated for induction therapy of moderate-to-severe active CD where other treatments are ineffective

► BioVersys*(FDA, Fast Track)*

BioVersys obtain Fast Track designation from FDA for BV100 to treat VABP and HABP caused by CRABC



●► **Scholar Rock** *(Breakthrough Therapy, Orphan Drug)*

Scholar Rock receives Fast Track and Orphan Drug designations from FDA for apitegromab to treat FSHD

●► **Juniper Biosciences** *(FDA, Breakthrough Therapy)*

FDA grants Breakthrough Therapy designation to Juniper Bioscience's JBS-003, a hypoxia tracer to guide de-escalated radiation therapy in patients with HPV-positive OPC

●► **Tarsus** *(Acquisition)*

Tarsus acquires Alkeus Pharmaceuticals, adding worldwide rights to ALK-001 that reduces toxic dimer accumulation, expanding its leadership in eye care

●► **Novartis** *(Phase 3, Results)*

Novartis' Ph3 REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing MS demonstrated superiority vs. teriflunomide in reducing ARR and inflammatory brain lesions, with a favourable safety profile



●▶ HUTCHMED*(Collaboration)*

Hutchmed collaborates with GSK to develop and commercialize HMPL-A830, with USD 110M paid upfront

●▶ Biocytogen*(Collaboration)*

Biocytogen collaborates with Qilu Pharmaceutical to license a fully human VHH antibody and to support its research and development of innovative therapeutics in the neuroscience field

●▶ Cipla*(Collaboration)*

Cipla collaborates with Chia Tai Tianqing Pharmaceutical, a subsidiary of SBP Group, to license and supply TQB2102 in India, South Africa and 5 other emerging markets

●▶ Simcere*(Collaboration)*

Simcere collaborates with Roche to develop and commercialize SIM0660, for an upfront of USD 75M to provide broad coverage across B-cell mediated diseases

